Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma

Our plain-English summary of Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma, by T. Kato, I. Tanaka, H. Huang, et al (International Journal of Molecular Sciences, 2025).

The study

• Authors: T. Kato, I. Tanaka, H. Huang, S. Okado, Y. Imamura, Y. Nomata, H. Takenaka, H. Watanabe, Y. Kawasumi, K. Nakanishi, Y. Kadomatsu, H. Ueno, S. Nakamura, T. Mizuno, T.F. Chen-Yoshikawa
• Journal: International Journal of Molecular Sciences
• Published: 2025;26(9)
• Type of article: Review
• Cited by: 8 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Mesothelioma is characterized by the inactivation of tumor suppressor genes, with frequent mutations in neurofibromin 2 (NF2), BRCA1-associated protein 1 (BAP1), and cyclin-dependent kinase inhibitor 2A (CDKN2A). These mutations lead to disruptions in the Hippo signaling pathway and histone methylation, thereby promoting tumor growth. NF2 mutations result in Merlin deficiency, leading to uncontrolled cell proliferation, whereas BAP1 mutations impair chromatin remodeling and hinder DNA damage repair. Emerging molecular targets in mesothelioma include mesothelin (MSLN), oxytocin receptor (OXTR), protein arginine methyltransferase (PRMT5), and carbohydrate sulfotransferase 4 (CHST4). MSLN-based therapies, such as antibody-drug conjugates and immunotoxins, have shown efficacy in clinical trials. OXTR, upregulated in mesothelioma, is correlated with poor prognosis and represents a novel therapeutic target. PRMT5 inhibition is being explored in tumors with MTAP deletions, commonly co-occurring with CDKN2A loss. CHST4 expression is associated with improved prognosis, potentially influencing tumor immunity. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown promise in some cases; however, resistance mechanisms remain a challenge. Advances in multi-omics approaches have improved our understanding of mesothelioma pathogenesis. Future research will aim to identify novel therapeutic targets and personalized treatment strategies, particularly in the context of epigenetic therapy and combination immunotherapy.

In plain English

This article was a review, not a new study. Authors from Nagoya University summarized published research on mesothelioma, which the article describes as mainly affecting the pleura and causally linked to asbestos exposure. It did not explain how the studies it discusses were chosen. It described genes that are often switched off in mesothelioma, citing reports of BAP1 inactivation in about 65% of cases and homozygous CDKN2A deletions in 50–100% of cases. It surveyed proposed drug targets, including mesothelin, the oxytocin receptor and PRMT5, and discussed CHST4 mainly as a possible marker of longer survival. It cited an earlier study, by several of the same authors, of 23 surgical samples. In that study, patients with higher CHST4 scores had median overall survival of 107.8 months, versus 38.0 months with lower scores. The review also summarized immunotherapy trials; in CheckMate 743, median survival was 18.1 months with nivolumab plus ipilimumab, compared with 14.1 months with standard chemotherapy. The review noted that mesothelin blood tests alone are insufficient for diagnosis. The authors concluded that survival gains remain modest because there are few large randomized trials and patients differ widely.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published laboratory and clinical research, with no new data and no stated method for selecting studies
• Who was studied: No study population of its own; the review discusses published studies of mesothelioma (mostly pleural) in patients, tumor samples, cell lines and mice
• Exposure: Not an exposure study. The review describes asbestos and other mineral fibers as causes and discusses inflammation as a mechanism. It focuses on genes, drug targets and treatments rather than fiber types or doses.
• Main results:
  • Citing other studies, the review reports that BAP1 is inactivated in approximately 65% of mesothelioma cases
  • Citing other studies, the review reports that CDKN2A is the most frequently inactivated tumor suppressor gene in mesothelioma, with homozygous deletions in 50–100% of cases
  • Citing other studies, the review reports that about 77% of patients with epithelial mesothelioma tested positive for mesothelin, which was not seen in sarcomatoid tumors
  • The review states that mesothelin blood tests alone are insufficient for diagnosing mesothelioma
  • The review presents CHST4 mainly as a possible indicator of favorable overall survival, identified from an analysis of the TCGA mesothelioma dataset, with a hypothesized role in tumor immunity
  • A cited earlier study examined 23 surgical samples from patients who underwent complete macroscopic resection. Patients with higher CHST4 scores had a median overall survival of 107.8 months, compared with 38.0 months for patients with lower scores.
  • In the cited CheckMate 743 trial, first-line nivolumab plus ipilimumab gave a median survival of 18.1 months, compared with 14.1 months for standard chemotherapy, particularly among patients with nonepithelioid mesothelioma
  • In the cited MiST2 phase II trial of abemaciclib in p16-deficient mesothelioma, disease control was reported in 54% of patients within 12 weeks
  • The cited COMMAND phase II trial of the FAK inhibitor defactinib recruited 344 patients with mesothelioma. The review states that low levels of Merlin did not improve disease outcomes in this trial.
• The authors' conclusion: The authors concluded that, despite promising developments, improvements in patient survival remain modest. They attributed this to the limited number of large-scale randomized trials and considerable differences between patients. They called for well-controlled, multicenter trials and individualized treatment.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Mesothelioma, Tumor Suppressor Gene, BAP1, CDKN2A, Hippo Signaling Pathway, Merlin, Mesothelin, Clinical Trial.

Related studies

• Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers — M. Maeda, O. Hino (2006)
• Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours — Y. Chen, Z. Gao, et al. (2024)
• Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing — G. Froechlich, C. Gentile, et al. (2021)
• Pan-cancer profiles of mesothelin (MSLN) unveil diagnostic potential and therapeutic targetability of pancreatic adenocarcinoma — M.R. Sheikh, B. Mistry, et al. (2026)
• The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression — V. Fontana, A. Vigani, et al. (2019)
• CHST4 Gene as a Potential Predictor of Clinical Outcome in Malignant Pleural Mesothelioma — S. Okado, T. Kato, et al. (2024)

Browse more research in International Journal of Molecular Sciences, or return to medical research.